RecallRadar

FDA Drug recall D-1219-2022

NAD+ 200mg/mL, 10mL-vial, Refrigerate, Tailor Made Compounding

On 2022-07-20 the FDA classified a Class II recall of NAD+ 200mg/mL, 10mL-vial, Refrigerate, Tailor Made Compounding by Tmc Acquisition, citing lack of Assurance of Sterility.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1219-2022
ClassificationClass II
Statusongoing
Initiated2022-03-07
Published2022-07-20
Last updated2026-09-13 11:52 UTC
CompanyTmc Acquisition
DistributionUS

Product

NAD+ 200mg/mL, 10mL-vial, Refrigerate, Tailor Made Compounding

Reason

Lack of Assurance of Sterility

Identifiers

code_info
Batch#: 10072110A2, 10142102A2, Exp 3/22/2022; 01112205A1, 11112123A1, Exp 4/30/2022; 11222114A1, 11172107A1, 11182120A…Batch#: 10072110A2, 10142102A2, Exp 3/22/2022; 01112205A1, 11112123A1, Exp 4/30/2022; 11222114A1, 11172107A1, 11182120A2, Exp 5/7/2022; 01102207A1, 01122211A1, Exp 5/11/2022; 12162119A1, 12162121A1, Exp 5/24/20220; 02022223A2, Exp 6/30/2022; 03012204A1, Exp 8/23/2022; 03082249B, Exp 9/4/2022; 03092226B, 03092236B, Exp 9/5/2022.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1219-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.